
FIG. 1


Progressive mCRPC
PSMA+
Previous taxane therapy and previous novel androgen axis therapy
Best supportive/ best standard of care
177Lu-PSMA-617 + Best supportive/best standard of care
2:1 randomization
Best supportive/best standard of care
1st interim 50% events
2nd interim 70% events
Final analysis